Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and Chronic Kidney Disease (CKD)
Main finding · Composite anemia outcomesResult — go to the resultHazard ratio 0.81 95% CI 0.73–0.90Authors' conclusion
In this multi-institutional cohort study with target trial emulation, SGLT2 inhibitors were associated with a decreased risk of composite anemia outcomes, especially anemia event occurrences. SGLT2 inhibitors may be considered as an adjunct therapy to reduce anemia incidence in patients with T2D and CKD.
Study context
- Population
- Adults with T2D and CKD stages 1 to 3 initiating SGLT2i or GLP-1 RA 2016–2021, Chang Gung Medical Foundation, Taiwan
- Participants
- 13,799 adults
- Exposure
- SGLT2i vs GLP-1 RA initiation
- SGLT2 inhibitorsn = 12,331
- GLP-1 RAsn = 1,468reference
- Outcome
- Composite of anemia outcomes:
- Anemia event occurrence (hemoglobin level <12-13 g/dL or ICD diagnosis codes)
- Anemia treatment initiation
- Follow-up
- Median 2.5 years
Methodological detailstarget trial emulation, multi-institutional
- Target trial emulation
- Multi-institutional
Main finding
Composite anemia outcomes
Hazard ratio
0.81
95% CI 0.73–0.90
SGLT2ivs GLP-1 RA
HR 0.81 (95% CI 0.73–0.90)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Anemia eventsSGLT2ivs GLP-1 RA | 0.79 (0.71–0.87) | |
| Anemia treatment initiationSGLT2ivs GLP-1 RA | 0.99 (0.83–1.19) | |
| 0.512Hazard ratio (log scale) |
Hematological parameters (hemoglobin, hematocrit, RBC count) · up to 3 years
- Changes in hematological parameters supported the primary analyses
Original publication
Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD. JAMA Netw Open. Published 4 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →